middle.news
Imugene’s azer-cel data gains momentum despite a tight cash position
9:43am on Friday 30th of October, 2026 AEDT
•
Biotechnology
Read Story
Imugene’s azer-cel data gains momentum despite a tight cash position
9:43am on Friday 30th of October, 2026 AEDT
Key Points
Azer-cel Cohort 3 records six responses among seven evaluable patients
Cohort 2 reports an 81% overall response rate after quarter end
A$11.12 million placement completed at A$0.095 a share
A$5.245 million cash balance against A$7.495 million quarterly operating outflow
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE